Compare GAB & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAB | MLTX |
|---|---|---|
| Founded | 1986 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | 2020 |
| Metric | GAB | MLTX |
|---|---|---|
| Price | $5.77 | $16.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $27.50 |
| AVG Volume (30 Days) | 844.3K | ★ 963.5K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 10.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.28 | $5.95 |
| 52 Week High | $6.37 | $62.75 |
| Indicator | GAB | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | 37.41 |
| Support Level | $5.46 | $15.54 |
| Resistance Level | $6.19 | $16.69 |
| Average True Range (ATR) | 0.08 | 0.89 |
| MACD | 0.01 | -0.21 |
| Stochastic Oscillator | 87.50 | 14.25 |
Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.